Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with Guselkumab

Author(s): Matteo Megna, Gabriella Fabbrocini, Lucia Gallo, Angela Patrì and Angelo Ruggiero*

Volume 17, Issue 4, 2022

Published on: 14 April, 2022

Page: [390 - 392] Pages: 3

DOI: 10.2174/1574886317666220307112926

Price: $65

Abstract

Introduction: Psoriasis is a chronic inflammatory skin disease requiring long-term treatment. However, there are approximately 71 million individuals with chronic HCV infection worldwide. In psoriatic patients affected by chronic HCV infection, conventional systemic drugs may be frequently contraindicated, while data on biologics use are limited.

Case Presentation: The case of a 48-year-old Caucasian man suffering from a severe form of plaque psoriasis and affected by a chronic-HCV-infection treated with guselkumab has been reported. Despite a huge improvement of the skin lesions (PASI reduced from 18 to 2), guselkumab was discontinued due to an HCV-infection reactivation after 3 months of treatment.

Conclusion: To the best of our knowledge, this is the first case report of the use of guselkumab in an HCV psoriatic patient. Further studies are needed to evaluate the safety of guselkumab in chronic HCV patients.

Keywords: Psoriasis, anti-IL-23, guselkumab, hepatitis C, hepatitis C reactivation, PASI.

« Previous Next »
[1]
Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2017; 31(5): 774-90.
[http://dx.doi.org/10.1111/jdv.14114] [PMID: 28244153]
[2]
Pawlotsky JM, Negro F, Aghemo A, et al. European Association for the Study of the Liver (EASL) recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69: 461-511.
[http://dx.doi.org/10.1016/j.jhep.2018.03.026]
[3]
Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016; 22(28): 6444-55.
[http://dx.doi.org/10.3748/wjg.v22.i28.6444] [PMID: 27605880]
[4]
Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: Practical considerations. Am J Clin Dermatol 2019; 20(6): 829-45.
[http://dx.doi.org/10.1007/s40257-019-00457-3] [PMID: 31222626]
[5]
Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168(3): 609-16.
[http://dx.doi.org/10.1111/bjd.12045] [PMID: 22985451]
[6]
Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Guselkumab and risankizumab for psoriasis: A 44-week indirect real-life comparison. J Am Acad Dermatol 2021; 85(4): 1028-30.
[7]
Megna M, Fabbrocini G, Cinelli E, Camela E, Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: An Italian 44-week real-life experience. J Dermatolog Treat 2020; 1-5.
[http://dx.doi.org/10.1080/09546634.2020.1800577] [PMID: 32705907]
[8]
Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study. Dermatol Ther 2021; 34(1): e14673.
[http://dx.doi.org/10.1111/dth.14673] [PMID: 33314658]
[9]
Megna M, Fabbrocini G, Ruggiero A, Cinelli E. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study. Dermatol Ther 2020; 33(6): e14144.
[http://dx.doi.org/10.1111/dth.14144] [PMID: 32761740]
[10]
Duncan JR, Orlowski TJ, Elewski BE. Safety of guselkumab in hepatitis B virus infection. Dermatol Online J 2019; 25(10): 13030/qt47h636rx.
[http://dx.doi.org/10.5070/D32510045827]
[11]
Meng P, Zhao S, Niu X. Involvement of the interleukin-23/interleukin-17 axis in chronic hepatitis C virus infection and its treatment re-sponses. Int J Mol Sci 2016; 17(7): 1070.
[12]
Ashrafi Hafez A, Ahmadi Vasmehjani A, Baharlou R, et al. Analytical assessment of interleukin - 23 and -27 cytokines in healthy people and patients with hepatitis C virus infection (genotypes 1 and 3a). Hepat Mon 2014; 14(9): e21000.
[http://dx.doi.org/10.5812/hepatmon.21000] [PMID: 25386199]
[13]
Wang JM, Shi L, Ma CJ, et al. Differential regulation of interleukin-12 (IL-12)/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection. J Virol 2013; 87(8): 4372-83.
[http://dx.doi.org/10.1128/JVI.03376-12] [PMID: 23388728]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy